source
- EMA issues new guideline on assessing gastrointestinal drug interaction risksThe European Medicines Agency has released a guideline that outlines how to evaluate drug interactions that occur in the gastrointestinal (GI) tract. The document focuses on extrinsic factors such…
- Axoltis Phase 2 ALS Trial Fails Primary Endpoint Though Shows Some Secondary TrendsAxoltis Pharma reported that its phase 2 study of the synthetic peptide NX210c in amyotrophic lateral sclerosis did not meet its primary goal. The double‑blind, randomized trial enrolled 82 French…